Previous 10 | Next 10 |
- Trilaciclib significantly reduced myelosuppression and need for related supportive care interventions for patients with small cell lung cancer (SCLC) receiving chemotherapy - New Drug Application (NDA) submission for trilaciclib in SCLC on track for completion in 2Q20 RESEARCH T...
G1 Therapeutics, Inc. (GTHX) Q1 2020 Earnings Conference Call May 06, 2020, 16:30 ET Company Participants Jeff Macdonald - Senior Director, IR & Corporate Communications Mark Velleca - CEO, President & Director Rajesh Malik - Chief Medical Officer, SVP, R&D Jennifer...
The following slide deck was published by G1 Therapeutics, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Image source: The Motley Fool. G1 Therapeutics, Inc. (NASDAQ: GTHX) Q1 2020 Earnings Call May 6, 2020 , 4:30 p.m. ET Operator Continue reading
G1 Therapeutics (NASDAQ: GTHX ): Q1 GAAP EPS of -$0.82 beats by $0.16 . More news on: G1 Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
New Drug Application (NDA) submission for trilaciclib in small cell lung cancer on track for 2Q20 Rintodestrant combination trial with palbociclib expected to initiate in 2Q20 Management to host webcast and conference call today at 4:30 p.m. ET RESEARCH TRIANGLE PARK, N.C., May ...
RESEARCH TRIANGLE PARK, N.C., April 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2020 on Wednesd...
RESEARCH TRIANGLE PARK, N.C., April 07, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M.D., Ph.D. will present a company update at the 19 th Annual Needham Virtual Healthcare ...
- Jack Bailey appointed to Board of Directors - Soma Gupta joins as Chief Commercial Officer - Company reports inducement grant under Nasdaq Listing Rule 5635 (c)(4) RESEARCH TRIANGLE PARK, N.C., March 12, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX...
Image source: The Motley Fool. G1 Therapeutics, Inc. (NASDAQ: GTHX) Q4 2019 Earnings Call Feb 26, 2020 , 4:30 p.m. ET Operator Continue reading
News, Short Squeeze, Breakout and More Instantly...
G1 Therapeutics, Inc. (NASDAQ:GTHX) shares are trading higher Thursday amid M&A blog speculation of a takeover offer. What To Know: Accor...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...